Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell

Immuneering (NASDAQ:IMRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other equities analysts have also commented on the stock. Needham & Company LLC raised their price objective on shares of Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Mizuho set a $12.00 target price on Immuneering in a report on Wednesday, October 29th. Leerink Partnrs upgraded Immuneering to a “strong-buy” rating in a report on Friday, October 31st. Oppenheimer upped their price target on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Immuneering in a research note on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immuneering has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Down 0.4%

NASDAQ:IMRX opened at $5.65 on Friday. The stock has a fifty day simple moving average of $6.45 and a 200 day simple moving average of $5.30. The firm has a market capitalization of $364.82 million, a price-to-earnings ratio of -3.17 and a beta of 0.46. Immuneering has a 1-year low of $1.10 and a 1-year high of $10.08.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Equities analysts predict that Immuneering will post -1.86 earnings per share for the current year.

Insider Transactions at Immuneering

In other news, Director Peter Feinberg bought 7,500 shares of the stock in a transaction on Friday, October 3rd. The shares were purchased at an average price of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the purchase, the director directly owned 156,766 shares of the company’s stock, valued at $1,045,629.22. This trade represents a 5.02% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired a total of 20,800 shares of company stock worth $143,754 over the last ninety days. 22.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immuneering

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP acquired a new stake in shares of Immuneering during the 3rd quarter valued at about $717,000. CIBC Private Wealth Group LLC raised its position in Immuneering by 233.7% during the third quarter. CIBC Private Wealth Group LLC now owns 50,051 shares of the company’s stock valued at $350,000 after acquiring an additional 35,051 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Immuneering in the third quarter valued at approximately $350,000. Heights Capital Management Inc. acquired a new stake in Immuneering in the third quarter valued at approximately $140,000. Finally, Woodline Partners LP bought a new stake in Immuneering in the third quarter worth approximately $1,050,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.